Reduction of Microglia-Mediated Neurotoxicity by KCa3.1 Inhibition
AssigneeThe Regents of the University of California
InventorsHeike Wulff, Lee-Way Jin, Izumi Maezawa
Life of this patent
Estimating the term…
Abstract
Methods for deterring microglia-mediated neurotoxicity in a human or non-human animal subjects comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel KCa3.1 in microglia, such as in subjects how suffer from neurodegenerative diseases (e.g., Alzeheimer's Disease) or ischemic/anoxic/hypoxic conditions. The inhibition or blocking of the KCa1.3 channels may be accomplished by administering a KCa3.1 inhibiting substance, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34).
Claims16
A method for deterring microglia-mediated neurotoxicity in a human or non-human animal subject, said method comprising the step of inhibiting or blocking the intermediate-conductance calcium-activated potassium channel KCa3.1 in microglia.
The use of 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (TRAM-34) in the manufacture of a pharmaceutical preparation for deterring microglia-mediated neurotoxicity in a human or non-human animal subject by inhibiting or blocking the intermediate-conductance calcium-activated potassium channel KCa3.1 in microglia.
Dependencies are inferred from the claim text.